Sector News

Nestlé unveils platform providing diet-related health data for 190 countries

November 28, 2021
Life sciences

Nestlé and the Friedman School of Nutrition Science and Policy at US-based Tufts University have launched the Global Nutrition and Health Atlas (GNHA), a new online platform that provides free access to global nutrition and health data for over 190 countries.

The GNHA supports groups that need easily accessible nutrition and health information, such as stakeholders, researchers, health practitioners, policymakers and advocates for healthy nutrition.

“The platform is a place to drive innovation and for people to collaborate. Many data platforms are restrictive, isolated or stagnant,” says Elena Naumova, chair of the division of nutrition data science at Friedman School.

“However, with the Atlas, one can merge information from multiple sources to pull data from different locations and years. Also, one can get tips on how to use it, and this usability supports the wide array of health and nutrition needs around the world.”

Collecting and visualizing data
The GNHA includes data from established sources, including international agencies, NGOs, academic institutes and peer-reviewed studies.

“At Nestlé, in addition to our research partnerships, we draw on public health data to develop science-based nutritional concepts for people across life stages around the world,” says Eline Van Der Beek, head of Nestlé Institute of Health Sciences.

“This platform makes it easy for Nestlé scientists, as well as academic researchers and other external stakeholders, to access reliable data in a quick, interactive and user-friendly way.”

The platform collects and visualizes data on six nutrition and health dashboards, including demographics, dietary intake, nutritional status, health status, health economics and food sustainability.

Each dashboard features data shown in maps and charts to reflect characteristics in geography, frequency and time trends. All dashboards can be downloaded in various formats for further circulation.

Accurate labeling and nutrition profiling
Key industry players have made efforts to ensure accurate F&B labeling and consumer understanding of nutrient profiles.

Last month, the Friedman School of Nutrition Science and Policy at Tufts University developed the Food Compass. A new nutrition profiling system aims to encourage consumers and food companies to choose and produce healthier foods.

In the same month, Action on Salt and Sugar called for the UK government to make front-of-pack nutrition labels mandatory without delay following a systematic review and meta-analysis.

Meanwhile, the European Consumer Organization recently raised the need for accurate food labeling for the children’s food sector as it found that children’s packaging praised unhealthy food consumption.

By Nicole Kerr


comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend